Schneeweiss A - Search Results

1

On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.

Sinn BV, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, Schmitt W, Marmé F, Schem C, Solbach C, Stickeler E, Tesch H, Fasching PA, Schneeweiss A, Müller V, Holtschmidt J, Nekljudova V, Loibl S, Denkert C. Sinn BV, et al. Among authors: schneeweiss a. Breast Cancer Res. 2024 Sep 24;26(1):138. doi: 10.1186/s13058-024-01883-w. Breast Cancer Res. 2024. PMID: 39317942 Free PMC article. Clinical Trial.

2

Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer.

Huober J, Schneeweiss A, Hohaus S, Wittmann G, Meyer A, Martin S, Goldschmidt H, Bastert G, Haas R, Wallwiener D. Huober J, et al. Among authors: schneeweiss a. J Cancer Res Clin Oncol. 1998;124(12):690-4. doi: 10.1007/s004320050233. J Cancer Res Clin Oncol. 1998. PMID: 9879830 Clinical Trial.

3

Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.

Hohaus S, Funk L, Martin S, Schlenk RF, Abdallah A, Hahn U, Egerer G, Goldschmidt H, Schneeweiss A, Fersis N, Kaul S, Wallwiener D, Bastert G, Haas R. Hohaus S, et al. Among authors: schneeweiss a. Br J Cancer. 1999 Mar;79(9-10):1500-7. doi: 10.1038/sj.bjc.6690239. Br J Cancer. 1999. PMID: 10188897 Free PMC article.

4

Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.

Schneeweiss A, Goerner R, Hensel MA, Lauschner I, Sinn P, Kaul S, Egerer G, Beldermann F, Geberth M, Solomayer E, Grischke EM, Haas R, Ho AD, Bastert G. Schneeweiss A, et al. Biol Blood Marrow Transplant. 2001;7(6):332-42. doi: 10.1016/s1083-8791(01)80004-5. Biol Blood Marrow Transplant. 2001. PMID: 11464976 Free article.

5

Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support.

Hensel M, Schneeweiss A, Sinn HP, Egerer G, Kornacker M, Solomayer E, Haas R, Bastert G, Ho AD. Hensel M, et al. Among authors: schneeweiss a. Stem Cells. 2002;20(1):32-40. doi: 10.1634/stemcells.20-1-32. Stem Cells. 2002. PMID: 11796920

6

Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose.

Schneeweiss A, Hensel M, Sinn P, Khbeis T, Haas R, Bastert G, Ho AD. Schneeweiss A, et al. Ann Oncol. 2002 May;13(5):679-88. doi: 10.1093/annonc/mdf168. Ann Oncol. 2002. PMID: 12075735 Free article.

7

P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support.

Hensel M, Schneeweiss A, Sinn HP, Egerer G, Solomayer E, Haas R, Bastert G, Ho AD. Hensel M, et al. Among authors: schneeweiss a. Int J Cancer. 2002 Jul 20;100(3):290-6. doi: 10.1002/ijc.10478. Int J Cancer. 2002. PMID: 12115543

8

Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression.

Schneeweiss A, Sinn HP, Ehemann V, Khbeis T, Neben K, Krause U, Ho AD, Bastert G, Krämer A. Schneeweiss A, et al. Int J Cancer. 2003 Nov 10;107(3):346-52. doi: 10.1002/ijc.11408. Int J Cancer. 2003. PMID: 14506732

9

Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy.

Schneeweiss A, Katretchko J, Sinn HP, Unnebrink K, Rudlowski C, Geberth M, Beldermann F, Bastert G, Strittmatter HJ. Schneeweiss A, et al. Anticancer Drugs. 2004 Feb;15(2):127-35. doi: 10.1097/00001813-200402000-00005. Anticancer Drugs. 2004. PMID: 15075668

10

Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.

Schneeweiss A, Huober J, Sinn HP, von Fournier D, Rudlowski C, Beldermann F, Krauss K, Solomayer E, Hamerla R, Wallwiener D, Bastert G. Schneeweiss A, et al. Eur J Cancer. 2004 Nov;40(16):2432-8. doi: 10.1016/j.ejca.2004.08.004. Eur J Cancer. 2004. PMID: 15519516 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

678 results

Search Page

Filters